BMC endocrine disorders · 2026
Serum adiponectin and soluble intercellular adhesion molecule-1 in patients with diabetic foot ulcers: a retrospective cohort study on the evaluation of disease severity and prognosis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wu Juan, Lu Ying, Chen Ke
Аннотация
OBJECTIVE: This study assessed serum Adiponectin (APN) and Soluble Intercellular Adhesion Molecule-1 (sICAM-1) levels in diabetic foot ulcer (DFU) patients for evaluating disease severity and prognosis.
METHODS: In this retrospective cohort study, 92 DFU patients were assessed during a 6-month outcome evaluation period and categorized by ulcer healing into good prognosis (healed, n = 50) or poor prognosis (unhealed, n = 42). Serum APN and sICAM-1 levels were measured by Enzyme-Linked Immunosorbent Assay (ELISA) and and analyzed for correlations with disease severity and infection grades. Receiver Operating Characteristic (ROC) curves evaluated their predictive value for poor prognosis.
RESULTS: Serum APN was negatively correlated with infection and disease severity, whereas sICAM-1 exhibited a positive correlation. The good prognosis group had significantly higher APN and lower sICAM-1 levels compared to the poor prognosis group. Both biomarkers predicted poor prognosis: APN (Area Under the Curve (AUC) = 0.765), sICAM-1 (AUC = 0.841). Combining both markers yielded an AUC of 0.853.
CONCLUSION: Serum APN and sICAM-1 levels are associated with DFU severity and prognosis, supporting their potential as predictive biomarkers in clinical practice.
CLINICAL TRIAL NUMBER: Not applicable.
METHODS: In this retrospective cohort study, 92 DFU patients were assessed during a 6-month outcome evaluation period and categorized by ulcer healing into good prognosis (healed, n = 50) or poor prognosis (unhealed, n = 42). Serum APN and sICAM-1 levels were measured by Enzyme-Linked Immunosorbent Assay (ELISA) and and analyzed for correlations with disease severity and infection grades. Receiver Operating Characteristic (ROC) curves evaluated their predictive value for poor prognosis.
RESULTS: Serum APN was negatively correlated with infection and disease severity, whereas sICAM-1 exhibited a positive correlation. The good prognosis group had significantly higher APN and lower sICAM-1 levels compared to the poor prognosis group. Both biomarkers predicted poor prognosis: APN (Area Under the Curve (AUC) = 0.765), sICAM-1 (AUC = 0.841). Combining both markers yielded an AUC of 0.853.
CONCLUSION: Serum APN and sICAM-1 levels are associated with DFU severity and prognosis, supporting their potential as predictive biomarkers in clinical practice.
CLINICAL TRIAL NUMBER: Not applicable.